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1 We have previously demonstrated that nitric oxide (NO) triggers CD34þ -derived megakaryocyte
apoptosis. We here show that prostacyclin (PGI2) inhibits PAPA/NO-induced megakaryocyte death
detected by fluorescent microscopy and flow cytometry.
2 The cAMP-specific phosphodiesterase inhibitor, Ro 20-1724, and the permeable analog dibutyryl-
cAMP also delayed apoptosis. PGI2 effect was fully prevented when adenylyl cyclase activity was
suppressed by SQ 22536, and partially reversed by the permeable protein kinase A inhibitor PKI 14-22
amide. ELISA showed that while both PGI2 and NO alone or synergistically raised cAMP, only NO
was able to increase intracellular cGMP levels.
3 Treatment of megakaryocytes with PGI2 abolished both basal and NO-raised cGMP levels.
Addition of 8-pCPT-cGMP or activation of soluble guanylyl cyclase by BAY 41-2272 induced cell
death in a concentration-dependent manner, and ODQ, an inhibitor of guanylyl cyclase, prevented
both PAPA/NO- or BAY 41-2272-induced apoptosis. Specific cGMP phosphodiesterase inhibition
by Zaprinast or suppression of adenylyl cyclase by SQ 22536 enhanced the PAPA/NO proapoptotic
effect.
4 PGI2 completely inhibited NO-mediated generation and the increased activity of the cleaved form
of caspase-3.
5 In conclusion, our results demonstrate that contrary to their well-known direct and synergistic
inhibitory effects on platelets, PGI2 and NO regulate opposite megakaryocyte survival responses
through a delicate balance between intracellular cyclic nucleotide levels and caspase-3 activity control.
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Introduction
The role of nitric oxide (NO) and prostacyclin (PGI2) in
platelets has been extensively examined by in vitro and in vivo
studies (Radomski & Moncada, 1993; Vane & Botting, 1995).
In contrast, their effects on the platelet progenitor cell, the
megakaryocyte, as well as in megakaryocytopoiesis are less
known.
Concerning NO, Battinelli & Loscalzo (2000) and Battinelli
et al. (2001) described that NO induces apoptosis of mega-
karyocytic cell lines and promotes platelet formation. Using
CD34þ -derived megakaryocytes, we have demonstrated that
not only mature cells but also progenitors are susceptible to
undergo programmed cellular death when exposed to NO
(Schattner et al., 2001).
Regarding PGI2, the presence of its membrane receptor (IP)
on megakaryocytes has been demonstrated previously; it was
observed that IP appears in immature megakaryocytes and cell
maturation accompanies enhancement of its expression (Sasaki
et al., 1997). The functional role of IP during the different
stages of human megakaryocyte maturation is not known.
Cytoprotection is a PGI2 biological property described soon
after its discovery (Konturek et al., 1981; Bursch et al., 1989;
Divald et al., 1990). However, in these studies, cell damage was
attributed to cell necrosis. More recently, several reports
showed that it not only protects cells from necrosis but also
exerts antiapoptotic activity (Kroll et al., 1998; Meyer zu
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Vilsendorf et al., 2001; Cutler et al., 2003). Interestingly,
depending on the cell type and/or PGI2 receptor interaction
(cell surface IP or intracellular peroxisome proliferator-
activated receptors (PPARs)), PGI2 exerts anti- or proapop-
totic effects. Hatae et al. (2001) using embryonic kidney 293
cells demonstrated that while extracellular PGI2 exerted anti-
apoptotic effects through IP receptors, endogenous PGI2
triggered proapoptotic mechanisms through PPAR. In con-
trast, Cutler et al. (2003) demonstrated that stromal produc-
tion of PGI2 promotes survival of colonocytes through PPAR
d activation.
Considering that both NO and PGI2 are released in the bone
marrow milieu in the present study, we evaluated the potential
cytoprotective effect of PGI2 in NO-mediated megakaryocyte
apoptosis. We found that PGI2 prevents NO-induced mega-
karyocyte-programmed cellular death. This function is related
not only to the recognized ability of PGI2 to increase cAMP
levels but also to its capacity of interfering with NO-triggered
death signaling pathways such as increases in cGMP and
caspase-3 activation.
Methods
Materials
Myristoylated protein kinase A inhibitor 14–22 amide (PKI),
adenylyl cyclase inhibitor SQ 22536, cGMP-specific phospho-
diesterase inhibitor Zaprinast, guanylyl cyclase inhibitor 1H-
[1,2,4] oxadiazolo [4,3-a]quinoxalin-1-one (ODQ) and caspase
colorimetric substrate acetyl-Asp-Glu-Val-Asp-p-nitroanilide
(Ac-DEVD-pNA) were purchased from Calbiochem (San
Diego, CA, U.S.A.). BAY 41-2272 was a gift from Bayer
HealthCare (Leverkusen, Germany). Sp-8-(4-chlorophenylthio)
guanosine-30,50-cyclic monophosphate (8-pCPT-cGMP) was
from Biomol International LP (Plymouth Meeting, PA,
U.S.A.). Ethyleneglycol-bis(b-aminoethyl)-N,N,N0,N0-tetraace-
tic acid (EGTA), human a-thrombin, hirudin, ethylenediamine-
tetraacetic acid (EDTA), a specific phosphodiesterase (PDE)
IV inhibitor, 4-(3-butoxy-4-methoxybenzyl) imidazolidin-2-one
(Ro 20-1724) and N6,20-O-dibutyryladenosine 30,50-cyclic
monophosphate sodium salt (Dib-cAMP) were from Sigma
Chemical Co. (St Louis, MO, U.S.A.). 1-propanamine,3-(2-
hydroxy-2-nitroso-1-propylhydrazino) (PAPA/NO) and PGI2
(sodium salt) were from Cayman Chemical (Ann Arbor, MI,
U.S.A.). Thrombopoietin (TPO) was from Peprotech (Ver-
acruz, Mexico). Fluorescein isothiocyanate (FITC)-conjugated
monoclonal antibodies against CD34 (Clone 581), glycoprotein
(GP) IIb (CD41), P-selectin (CD62P), phycoerythrin (PE)-
conjugated anti-CD41, anti-GPIb (CD42b) and FITC- or PE-
conjugated isotypes were purchased from Beckman Coulter
(Miami, FL, U.S.A.). Mini-MACS, goat-anti-mouse magnetic
microbeads and human CD34 progenitor cell isolation kit were
from Miltenyi Biotec (Bergisch Gladbach, Germany). Direct
cAMP and cGMP kits were from Assay Designs (Ann Arbor,
MI, U.S.A.). von Willebrand factor (VWF) kit was from
Research Diagnostics Inc. (Flanders, NJ, U.S.A.). Anti-cleaved
(activated) caspase-3 (Asp175) antibody was purchased from
Cell Signaling Technology Inc. (Beverly, MA, U.S.A.). Rabbit
IgG was from Sigma Chemical Co. Swine FITC-conjugated
anti-rabbit immunoglobulins and anti-CD61 (Y2/51) were
from Dako A/S (Glostrup, Denmark).
Stock solutions of BAY 41-2272, Zaprinast and ODQ were
prepared in DMSO. Ro 20-1724 was solubilized in ethanol.
PGI2 was dissolved in a basic phosphate-buffered saline (PBS,
pH 10), PAPA/NO in NaOH (0.01M) and TPO in Tris
(10mM, pH 8.0). All other drugs were dissolved in MilliQ
water. Further dilutions of all reagents were carried out in
Iscove’s modified Dulbecco’s medium (IMDM). When drugs
were dissolved in DMSO or ethanol, its concentration never
exceeded 0.04%. This DMSO or ethanol concentration did not
elicit megakaryocyte apoptosis.
Isolation of CD34þ cells
Umbilical cord blood was collected during normal full-term
deliveries with informed consent of the mother and used within
24 h. After collection, samples were diluted one-third in PBS
and centrifuged. The upper phase containing platelets was
removed. Low-density mononuclear cells were prepared by
centrifugation of the remaining blood over a Ficoll Hypaque
(1.077 g (cm3)1) gradient. Cells collected from the interface
were washed and resuspended in PBS containing EDTA
(2mM) (PBS/EDTA) and human albumin (0.5% (w v1)).
CD34þ cells were purified using a magnetic cell-sorting system
(Miltenyi Biotec) in accordance with the manufacturer’s
recommendations. The purity of the CD34þ -enriched popula-
tion was determined by immunolabeling the cells with FITC-
conjugated anti-CD34 monoclonal antibody that reacted
with an epitope other than the antibody used for separation.
After two Mini-MACS column separations, the purity of cell
suspension was determined by flow cytometry and ranged
typically between 95 and 99% for CD34þ .
Megakaryocyte in vitro expansion and purification
Freshly isolated CD34þ cells (5 104ml1) were cultured
in a six-well plate at 371C in a humidified atmosphere with
5% CO2 as described previously (Sanz et al., 2001) with some
modifications. Briefly, CD34þ cells were cultured in IMDM
containing glutamine (2mM), human serum (5%) obtained
by recalcification of citrated platelet-free plasma, TPO
(25 ngml1) and antibiotics (growth medium). At day 6, cell
density was readjusted to 2.5 105ml1 with fresh growth
medium. After 4–6 days, flow cytometry studies showed that
more than 75% of cells were megakaryocytes (CD41þ )
presenting maturation markers such as: (1) increased CD41
intensity (mean fluorescence intensity expressed as arbitrary
units: 205726, 11917198, 17557266, 40587118 at days 3, 6,
9 and 12 of culture, n¼ 4), (2) CD42b expression (7275%
of the megakaryocyte population determined by two-color
flow cytometry analysis, n¼ 5) and (3) P-selectin expression
and VWF release after a-thrombin stimulation (Figure 6). In
addition, cultures showed proplatelet-bearing megakaryocytes.
Apoptosis was induced without changing the growth medium,
at 371C in a humidified atmosphere with 5% CO2.
In selected experiments and for cyclic nucleotide measure-
ment, megakaryocytes were further purified by immunomag-
netical positive selection using anti-CD61 antibody (10min on
ice) and goat-anti-mouse magnetic microbeads (20min, 41C)
(Schmitz et al., 1994). After Mini-MACS column separation,
the purity of the final cell suspension was determined by
flow cytometry and was typically between 90 and 95%. Cell
viability was greater than 90%.
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Quantitation of cellular apoptosis and viability
by fluorescence microscopy
Cells (5 105ml1) were labeled with a mixture of the
fluorescent DNA-binding dyes acridine orange (100 mgml1)
to determine the percentage of cells that had undergone
apoptosis and ethidium bromide (100mgml1) to differentiate
between viable and nonviable cells. With this method,
nonapoptotic cell nuclei show structural variations in fluores-
cence intensity that reflect the distribution of euchromatin and
heterochromatin. In contrast, apoptotic nuclei exhibit highly
condensed chromatin uniformly stained by acridine orange
(Coligan et al., 1994). To assess the percentage of cells showing
morphologic features of apoptosis, at least 300 cells were
scored in each experiment.
Quantitation of megakaryocyte apoptosis by propidium
iodide staining and flow cytometry
Megakaryocyte population displaying a hypodiploid DNA
peak was determined as described previously (Schattner et al.,
2001). Briefly, cells (1 106ml1) were labeled with FITC-
conjugated anti-CD41 or isotype-matched IgG and fixed
in 0.5% paraformaldehyde. DNA was then stained by cell
incubation for 20min at 41C with 400 ml of a solution
containing propidium iodide (50 mgml1 in 0.1% sodium
citrate) and 0.1% Triton X-100 for cell permeabilization. This
was followed by RNA digestion. The red fluorescence of
propidium iodide in individual nuclei of the CD41þ popula-
tion was measured by flow cytometry.
Analysis of caspase-3 activation by flow cytometry
Cells (1 106ml1) were first labeled with PE-conjugated anti-
CD41 or isotype-matched IgG and then fixed and permeabi-
lized using Fix & Perm kit (Beckman Coulter), following the
manufacturer’s instructions. After labeling with a polyclonal
antibody specific for the activated form of caspase-3 for 2 h at
room temperature, cells were washed and incubated with
secondary FITC-conjugated swine anti-rabbit immunoglobu-
lins for 30min at room temperature. As nonspecific binding
control, anti-cleaved caspase-3 antibody was replaced by a
similar concentration of rabbit IgG. The percentage of
activated caspase-3-expressing cells in the CD41þ population
was analyzed by two-color flow cytometry excluding debris
and platelets on the basis of their low light-scatter properties.
Ac-DEVD-pNA cleavage assay
Megakaryocytes (1 106ml1) were incubated for 5 h with
PAPA/NO or PGI2þPAPA/NO. Then, cells were washed
twice with PBS/EDTA and lysed with lysis buffer (50mM Tris-
HCl (pH 7.4), 1mM EDTA, 10mM EGTA, 10mM digitonin,
0.5mM phenylmethylsulfonyl fluoride, 1.5 mM aprotinin,
14.6 mM pepstatin and 63.9mM benzamidine). Lysates were
collected, clarified by centrifugation and caspase-3-like activity
in the supernatants was measured 2 h after substrate addition
by spectrophotometry. Substrate alone was used as blank and
subtracted from each sample. The caspase-catalyzed release of
pNA was monitored at 405 nm in a microtiter plate reader and
the cleavage activity was expressed as pNA absorbance units
(A405) per 106 cells.
cAMP and cGMP measurement
Purified megakaryocytes (5 105ml1) were stimulated with
PGI2, PAPA/NO or the combination of both drugs for 15min
at 371C. Triton X-100 (1%) in 0.1 N HCl was used as lysis
buffer. Acetylated intracellular cAMP or cGMP levels were
measured in cell lysates using a commercial enzyme-linked
immunosorbent assay (ELISA) kit according to the manufac-
turer’s instructions.
Megakaryocyte VWF release and P-selectin expression
measurements
Megakaryocytes (1 106ml1) were centrifuged in PBS/EDTA
for 10min at 200 g. Cells were then resuspended in IMDM
containing saturating concentrations of FITC-conjugated anti-
CD62P or isotype-matched IgG in the presence or absence
of PAPA/NO or PGI2. Cells were stimulated with a-thrombin
for 3min followed by the addition of hirudin. After 20min,
cells were immediately analyzed by flow cytometry. In VWF
experiments, after centrifugation, cells were resuspended in
IMDM in the presence or absence of PAPA/NO or PGI2.
After a-thrombin stimulation, the amount of VWF released
was measured in supernatants by ELISA. Results are
expressed as the percentage of VWF released by a-thrombin
stimulation (VWF values were extrapolated from a standard
curve plotted from serial dilutions of normal pooled plasma,
assuming a 10 mgml1 VWF concentration).
Statistical analysis
Data are expressed as means7s.e.m. and were analyzed by
one-way analysis of variance (ANOVA), followed by the
Newman–Keuls procedure to determine significant differences
between groups. P-values lower than 0.05 were considered
statistically significant.
Results
PGI2 reversion of NO-induced megakaryocyte apoptosis
The addition of PAPA/NO to megakaryocyte cultures
triggered apoptosis (ED50¼ 9874mM). Figures 1 and 2 show
that preincubation of cells with PGI2 significantly reduced
the NO-induced megakaryocyte apoptosis in a concentration-
dependent manner. In contrast, no significant antiapoptotic
effect was observed when PGI2 was added after the NO donor
(Table 1).
Although we have used megakaryocyte cultures with at least
75% of CD41þ cells and apoptosis was evaluated in this cell
population by using double stain flow cytometry, some
experiments were performed using highly purified megakar-
yocytes (X98%). Under these conditions, PGI2 (3 mM) showed
a similar pattern of apoptosis inhibition (18, 56 and 30% of
apoptotic cells, in control, PAPA/NO and PGI2þPAPA/NO
respectively, n¼ 2).
Role of cAMP in PGI2 antiapoptotic activity
The IP-receptor-mediated PGI2 signaling pathway involves
activation of adenylyl cyclase followed by an increase in
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intracellular cAMP levels (Best et al., 1977). In order to
examine whether cAMP was involved in the prevention of
apoptosis mediated by PGI2, we used a cAMP-specific PDE
inhibitor Ro 20-1724 and the permeable analog Dib-cAMP.
Like PGI2, both drugs significantly reduced NO-induced
apoptosis (Table 2). Moreover, preincubation (5min) with
the adenylyl cyclase inhibitor SQ 22536 (500 mM) abolished
PGI2 cytoprotection (SQ 22536 1271%, NO 5072%,
PGI2þNO 2471% and SQ 22536þPGI2þNO 4871% of
apoptosis, n¼ 3). As expected, treatment with PGI2 signifi-
cantly raised cAMP when compared to untreated cells. In a
lesser degree, PAPA/NO elicited the same response, and a
higher cAMP increase was observed when megakaryocytes
were treated with both drugs suggesting a synergistic effect
(Table 3). In order to evaluate whether cAMP increases
mediated by PAPA/NO serve as a self-regulatory mechanism
of NO-induced apoptosis, the NO proapoptotic effect was
evaluated in the presence of SQ 22536. Figure 3 shows that
blocking of adenylyl cyclase enhanced megakaryocyte sensi-
tivity towards PAPA/NO cytotoxic effect.
Role of PKA on PGI2-mediated cytoprotection
To investigate whether the cytoprotective effects of cAMP
involved PKA activation, megakaryocytes were incubated with
PKI (a PKA inhibitor). The antiapoptotic effect of PGI2 was
significantly reduced, although not completely suppressed,
suggesting that, at least in part, activation of PKA is a
downstream signal in the cAMP cascade that mediates the
PGI2 cytoprotective effect (Figure 4).
Regulation of cGMP megakaryocyte levels by NO
and PGI2
As the main pathway of intracellular NO signaling involves
an increase in cGMP (Loscalzo, 2001), we also evaluated PGI2
intracellular cGMP regulation. While the NO donor increased
cGMP, unexpectedly, PGI2 markedly diminished both basal
and NO-mediated increase in cGMP (Table 3). These findings
point out that not only an increase in cAMP but also an
abolition of NO-induced cGMP raised levels are involved in
PGI2 antiapoptotic effect.
cGMP, a mediator of NO-induced megakaryocyte
apoptosis
In our previous study, we reported that NO-induced mega-
karyocyte apoptosis seemed unrelated to cGMP because
treatment with 8-Br-cGMP (3–6mM) failed to trigger mega-
karyocyte apoptosis (Schattner et al., 2001). Since, in the
present study, reversion of NO-induced apoptosis by PGI2
correlated with marked cGMP downregulation, we re-exam-
ined the role of this nucleotide on megakaryocyte death, to
find that other cGMP analog, 8-pCPT-cGMP, increased the
percentage of apoptosis in a concentration-dependent manner
with an EC50¼ 230 mM (Figure 5a). When the activity of
soluble guanylyl cyclase was suppressed by ODQ, treatment of
megakaryocytes with PAPA/NO was markedly reduced
(Figure 5c). To further substantiate the possible involvement
of cGMP in the control of cell viability, we tested the effect of
BAY 41-2272, a direct activator of guanylyl cyclase (Stasch
et al., 2001). Figure 5b shows that BAY 41-2272 triggered
apoptosis in a concentration-dependent manner and it was
completely abrogated by pretreatment of megakaryocytes with
ODQ. On the other hand, Zaprinast (a cGMP-PDE inhibitor)
was capable of increasing the apoptotic effect of PAPA/NO
(Figure 5d).
Caspase-3 activation in NO-mediated cellular death
To further analyze the molecular mechanism involved in the
PGI2 antiapoptotic effect and considering that it was recently
demonstrated that senescent and apoptotic megakaryocytes
show high levels of activated caspase-3 (De Botton et al.,
2002), we next evaluated its expression in our experimental
model. Maximal induction of caspase-3 was seen 5 h after
NO-induced apoptosis (control 4.070.5%; NO 18.471.0%
of positive cells, n¼ 3, Po0.05) and was abolished by PGI2
(PGI2þNO 3.670.6% of positive cells, n¼ 3; Po0.05 vs NO
alone) (Figure 6). Considering that immunodetection of
caspase-3 active fragment not necessarily imply an evidence
of its enzymatic function, we next measured caspase-3 activity.
As shown in Table 4, NO-treated megakaryocytes revealed
more than four-fold increase in functional caspase-3 activity,
whereas PGI2 completely abolished it.
PGI2 and NO inhibit megakaryocyte activation responses
It is widely known that NO and PGI2 synergistically inhibit
platelet activation through impairments in Ca2þ mobilization
(Schwarz et al., 2001). To analyze the effect of these mediators
on non-nuclear-mediated megakaryocyte responses, we stu-
died PGI2 and NO regulation of a-thrombin-stimulated VWF
release or P-selectin externalization. Unlike their opposite
control of cell survival, both drugs independently and
synergistically decreased both activation responses either in
platelets (data not shown) or megakaryocytes (Figure 7).
Figure 1 PGI2 protects megakaryocytes from NO-induced apop-
tosis. PGI2 was added 1min before PAPA/NO (100 mM) and
megakaryocyte apoptosis was evaluated 18 h later by fluorescent
microscopy (open circles) or flow cytometry (solid squares) (n¼ 5).
All experiments were performed in duplicate.
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Discussion
The present study shows that PGI2 protects megakaryocytes
from NO-induced apoptosis. Our data showing that an
increase in cAMP by different agents significantly inhibited
NO-triggered megakaryocyte death and that PGI2 effect was
completely suppressed by adenylyl cyclase blockade strongly
indicate cAMP as the mediator of PGI2 antiapoptotic activity.
Moreover, partial suppression of PGI2 effect by PKA
inhibition suggests PKA as one of the downstream mediators
in this cAMP signaling transduction pathway. However, we
cannot rule out that other molecules could be involved. NO-
induced apoptosis was not inhibited when PGI2 was added
after the NO donor, indicating that cAMP is no longer
effective once the apoptotic process had started.
Although pro- and antiapoptotic effects of cAMP have been
previously described on other cells (Mcconkey & Orrenius,
1996), to the best of our knowledge, this is the first report
showing that cAMP inhibits NO-induced megakaryocyte
apoptosis.
Figure 2 Microscope and flow cytometry analysis of apoptosis. PGI2 (3 mM) was added 1min before PAPA/NO (100 mM). Data
shown are representative of five independent experiments performed in duplicate and arrows indicate apoptotic cells.
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The role of NO in the induction of the apoptotic cell death
program has been extensively studied; however, the underlying
mechanisms accounting for NO-induced cell toxicity are
controversial. Rabkin & Kong (2000) demonstrated that
H2O2 is involved in sodium nitroprusside-induced cardio-
toxicity. Peroxinitrite formation has also been considered
as a possible mediator of NO-induced neutrophil apoptosis
(Ward et al., 2000). However, other groups reported that
NO and cGMP analogs increase apoptosis in several cell
types (Pollman et al., 1996; Loweth et al., 1997; Wu et al.,
1997; Chiche et al., 1998; Suenobu et al., 1999; Kaminski
et al., 2004).
Surprisingly, we found that PGI2 negatively regulated
NO-mediated increase of cGMP levels. We also observed that
while a guanylyl cyclase activator (BAY 41-2272) or a cGMP
analog triggered megakaryocyte apoptosis, Zaprinast (a
cGMP-specific PDE inhibitor) enhanced PAPA/NO-induced
cell death. In addition, inhibition of guanylyl cyclase
completely suppressed BAY 41-2272-mediated megakaryo-
cyte death. All together, these results indicate that increases
in cGMP levels exert a proapoptotic effect and that this
second messenger is a major mediator of PAPA/NO death
mechanism. However, since cellular death induced by this
NO donor was not completely suppressed by ODQ, we do
not rule out that other radical species (e.g. superoxide,
peroxinitrite) could also be involved in the PAPA/NO
cytotoxic effect.
The observation that elevation of cGMP levels triggers
megakaryocyte-programmed cellular death also suggests that
PGI2 antiapoptotic activity is associated with both phenom-
ena: cAMP upregulation and cGMP downregulation. Further-
more, as in resting platelets (Jang et al., 2002), in unstimulated
megakaryocytes, cAMP levels were greater than those of
cGMP. While NO exposure reversed this relationship,
pretreatment of cells with PGI2 maintained cAMP levels
higher than cGMP. These data point out that the cAMP/
cGMP ratio may be critical to determine the cell survival/death
decision. In fact, the finding that both PGI2 and the NO donor
increase cAMP, but only NO triggers apoptosis, could be
Table 1 Loss of PGI2 antiapoptotic effect when
added after PAPA/NO
Treatments Apoptosis (%)
None 1673
PAPA/NO 4274*
PGI2 1min+PAPA/NO 2373
#
PAPA/NO 15min+PGI2 4275
z
Megakaryocytes were treated as indicated, and 18 h later, the
percentage of apoptosis was determined by flow cytometry
(n¼ 3). *Po0.05 vs none. #Po0.05 vs PAPA/NO alone.
zPo0.05 vs PGI2 1min+PAPA/NO alone.
Table 2 cAMP elevating drugs prevent megakaryo-
cyte apoptosis
Apoptosis (%)
Treatments None PAPA/NO
None 1472 5174*
PGI2 1271 2572
#
Ro 20-1724 1471 2772#
Dib-cAMP 1472 2472#
Megakaryocytes were incubated in the absence (none)
or presence of PAPA/NO (100mM). PGI2 (3mM), Dib-cAMP
(100mM) or Ro 20-1724 (10mM) were added 1, 1 and 30min,
respectively, before PAPA/NO. After 18 h, the percentage of
apoptosis was determined by flow cytometry (n¼ 4 in
duplicate). *Po0.05 vs none #Po0.05 vs PAPA/NO alone.
Figure 4 Role of PKA in cytoprotection mediated by PGI2.
Megakaryocytes were preincubated for 30min with PKI (100 nM)
before PGI2 (3 mM) and NO donor (100 mM PAPA/NO). Apoptosis
was evaluated by detection of hypodiploid nuclei in the CD41þ
population 18 h later (n¼ 4 in duplicate). *Po0.05 vs none;
#Po0.05 vs NO; zPo0.05 vs PGI2þNO.
Table 3 Regulation of intracellular cAMP and
cGMP levels
Treatments cAMP (nM) cGMP (nM)
None 0.2970.01 0.1070.01
PAPA/NO 0.4970.01* 4.0370.09*
PGI2 2.6870.08* Nondetectable
PGI2+PAPA/NO 5.0170.08
z,# 0.6070.02#
Acetylated cAMP or cGMP in megakaryocyte lysates were
determined 15min post treatment with PGI2 (3mM), PAPA/
NO (100 mM) or the combination of both drugs (PGI2 was
added 1min before NO) (n¼ 4 in duplicate). *Po0.05 vs
none. zPo0.05 vs PGI2 alone. #Po0.05 vs PAPA/NO. The
detection limit of the cGMP assay was 0.025 nM.
Figure 3 Role of cAMP in NO-induced apoptosis. Megakaryo-
cytes were preincubated in the presence (white bars) or absence
(black bars) of SQ 22536 (500 mM) for 5min before NO donor.
Apoptosis was evaluated by detection of hypodiploid nuclei in the
CD41þ population 18 h later (n¼ 5 in duplicate). *Po0.05 vs none;
#Po0.05 vs NO; &Po0.05 vs SQ 22536 alone.
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explained by the fact that NO-mediated cGMP increases
exceeded those of cAMP. The results showing that blockade of
adenylyl cyclase sensitized megakaryocytes for PAPA/NO
effects reinforce the notion that the NO-mediated cAMP
increases represent a negative feedback control of the
proapoptotic NO effects.
The ability of NO to increase cAMP as well as that of PGI2
to decrease cGMP levels indicates a crosstalk between cyclic
nucleotides. The concept that in cells of megakaryocytic
lineage, cAMP and cGMP downstream signaling events may
interfere with each other was previously demonstrated in
platelets (Maurice & Haslam, 1990; Grunberg et al., 1995).
These studies showed that NO-mediated platelet inhibition
involves not only cGMP but also cAMP increases due to
PDE3A activity inhibition by cGMP. Herein, we demon-
strated that a similar cAMP increase by NO occurs in
megakaryocytes, although the mechanism has not yet been
investigated. cGMP decreases by PGI2 have not been reported.
However, recent in vitro studies show that PDE5 (specific for
cGMP hydrolysis) can be phosphorylated by cGMP-PK and
by cAMP-PK, thus increasing its catalytic activity and
providing physiological negative feedback regulation of
intracellular cGMP levels (Corbin et al., 2000). The possibility
that similar PDE activation accounts for PGI2-mediated
downregulation of cGMP deserves further investigation.
Our findings demonstrating that cAMP and cGMP exert
opposite cellular actions in megakaryocytes are in sharp
contrast with the well-known synergistic inhibitory effect of
these second messengers on platelet activation (Radomski
et al., 1987; Schwarz et al., 2001). However, we also showed
that a-thrombin-mediated megakaryocyte activation (VWF
release and P-selectin expression) was inhibited directly and
synergistically by NO and PGI2. As apoptosis includes nuclear
events, it is not unlikely that, besides calcium signaling
pathway, downstream cyclic nucleotide signals in megakar-
yocytes include differential regulation of proteins involved in
cell cycle, so that in anucleated platelets, these effects would be
lacking. Interestingly, using another model, Wu et al. (1997)
have previously described a similar cAMP and cGMP
Figure 5 cGMP-mediated megakaryocyte apoptosis. (a) Megakar-
yocytes were treated with 8-pCPT-cGMP (n¼ 3 in duplicate). (b)
Cells were stimulated with BAY 41-2272 (n¼ 5). ODQ (500 mM) was
added 30min before stimulation (n¼ 3 in duplicate). (c) Apoptosis
(black bars) was induced by PAPA/NO (100 mM), and acetylated
cGMP (white bars) in megakaryocyte lysates was measured 15min
after NO addition. ODQ (500 mM) was added 30min before the NO
donor (n¼ 5). (d) Cells were preincubated in the presence (white
bars) or absence (black bars) of Zaprinast (40 mM) for 5min before
PAPA/NO and apoptosis was measured by flow cytometry (n¼ 6).
*Po0.05 vs none; #Po0.05 vs PAPA/NO; &Po0.05 vs Zaprinast
alone.
Figure 6 Inhibition of caspase-3 cleavage by cAMP raising agents.
Megakaryocytes were treated for 1min with PGI2 (3 mM) and further
incubated for 5 h with PAPA/NO (100 mM). Activated caspase-3 was
then detected by flow cytometry. Histograms show isotype (gray
area) or activated caspase-3-stained cells (black line) and are
representative of three similar experiments performed in duplicate.
Table 4 Regulation of caspase-3 activity
Treatments Ac-DEVD-pNA cleavage
(A405/106 cells)
None 0.05670.012
PAPA/NO 0.24070.023*
PGI2+PAPA/NO 0.07670.018
Megakaryocytes were exposed to drugs for 5 h and caspase-3
activity was determined by colorimetric detection of Ac-
DEVD-pNA cleavage (n¼ 3). *Po0.01 vs none or PGI2+
PAPA/NO.
R. Gabriel Pozner et al cAMP/cGMP regulates megakaryocyte apoptosis 289
British Journal of Pharmacology vol 145 (3)
opposing roles in the modulation of cardiac myocyte growth
and survival. It is important to note that in our experiments,
concentrations of NO donor required to trigger apoptosis were
higher than those generally used to exert other NO activities
such as inhibition of platelet aggregation or vascular relaxa-
tion (Moro et al., 1996). However, this observation is in
agreement with other studies performed not only in mega-
karyocytes (Battinelli & Loscalzo, 2000) but also in other cell
types (Wu et al., 1997; Jarry et al., 2004; Velardez et al., 2004).
It could be speculated that in vivo, these differences in NO
effects are related to eNOS or iNOS involvement in NO
generation.
Proteases of the caspase family represent the central
executioners of the apoptotic process. Recent evidence has
shown that in vitro grown megakaryocytes exhibit activation of
caspase-3 and -9 during their terminal stages of maturation
(De Botton et al., 2002). We found that while NO-induced
apoptosis increased the percentage of positive cells for the
active form of caspase-3 cells and its activity, PGI2 completely
prevented both effects. Our results showing caspase-3 involve-
ment in NO-mediated megakaryocyte apoptosis are in contrast
to earlier publications suggesting that although NO induces
Meg-01 apoptosis, it inhibits the protease activity possibly by
S-nitrosylation of the caspase active site (Battinelli & Loscalzo,
2000). However, this effect was not observed in other cell types
(Kim et al., 2003; Chae et al., 2004). A possible explanation for
the differences between our findings and those from Battinelli’s
group could be the megakaryocytic source employed in each
study (immortalized vs CD34þ -derived megakaryocytes).
Developing megakaryocytes are distributed within two main
compartments of the bone marrow: the osteoclastic niche
(immature progenitors) and the vascular niche (mature
megakaryocytes) (de Sauvage et al., 1996). The influence of
the bone marrow microenvironment on megakaryocyte devel-
opment and survival was recently examined by Avecilla et al.
(2004). They have demonstrated that stromal cell-derived
factor-1 (SDF-1) and fibroblast growth factor-4 (FGF-4)
allow localization of megakaryocyte progenitors to the bone
marrow vascular niche, promoting survival, maturation and
platelet release independently of TPO. A very interesting
feature of this study is that megakaryocytes and bone marrow
endothelium interaction is required since both chemokines
alone had no major effects. Moreover, because adhesion and
transendothelial migration mediated by FGF-4 and SDF-1,
respectively, were only partially blocked when adhesion
molecules were inhibited, they suggested that other molecules
released by vascular endothelium or extracellular matrix
components may support chemokine-mediated effects. As
we have shown that NO kills not only mature but also
megakaryocyte progenitors and CD34þ cells (Schattner et al.,
2001), NO apoptotic activity at early stages of megakaryocy-
topoiesis, in the osteoclastic niche, should be effectively
controlled to avoid thrombocytopenia. In early megakaryocy-
topoiesis stages, when PGI2 surface receptor is absent (Sasaki
et al., 1997), it may be speculated that the TPO survival signal
would be predominant. However, when megakaryocytes are
mobilized to the vascular niche, close contact with the marrow
sinus endothelial barrier would allow maximal exposure to
PGI2, which might contribute to the SDF-1- and FGF-4-
mediated megakaryocyte survival. Interestingly, it has been
demonstrated that SDF-1 triggers PGI2 release (Molino et al.,
2000). Whether PGI2 regulates megakaryocyte maturation and
platelet formation is currently under investigation in our
laboratory. Although our findings provide new concepts for
understanding megakaryocyte survival/death decision, addi-
tional experiments are required to determine the in vivo
physiopathological relevance of these processes.
In summary, we provide in vitro evidence that cGMP is a
key mediator of NO-induced megakaryocyte-programmed
cellular death and that caspase-3 activation is a downstream
effector. We also found that PGI2 prevents NO-induced
megakaryocyte death not only by increasing intracellular
Figure 7 Regulation of a-thrombin-stimulated VWF release or
P-selectin expression. Megakaryocytes were incubated with PGI2
(3 mM) and/or PAPA/NO (100 mM) for 1min and a-thrombin was
then added as indicated. Incubation was continued for 30min and
supernatants (a) or cells (b) collected for VWF assay or P-selectin
detection, respectively (n¼ 5 in duplicate). *Po0.05 vs none;
#Po0.05 vs a-thrombin alone; zPo0.05 vs PGI2þ a-thrombin and
NOþ a-thrombin.
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cAMP levels but also through its ability to antagonize NO-
triggered cGMP raises and caspase-3 activation. In contrast to
the well-known inhibitory synergistic effect in platelets, this is
the first report describing that, in their precursors, NO and
PGI2 regulate opposite responses.
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